Why Medicare is Finally Rethinking Weight Loss Drug Coverage

In 2003, the US Congress barred Medicare coverage of weight-loss medications. This followed problems with the weight loss medication known as Fen-Phen in the 1990s. Since then, GLP-1 drugs have gained popularity for weight loss, and researchers are finding a growing list of health benefits. This has led the Centers for Medicare and Medicaid Services (CMS), which oversees Medicare, to reconsider. CMS has introduced the Medicare GLP-1 Bridge program. This is a short-term pilot project to determine the financial and health impacts of Medicare paying for weight loss drugs.

The Financial Impact for Consumers

The program began July 1, 2026, and runs through December 31, 2027. It is available to Medicare Part D beneficiaries. They must be enrolled in a standalone prescription drug or Medicare Advantage plan that offers prescription drug coverage. The pilot project is operating outside of the standard Medicare Part D coverage. This means the copay for the GLP-1 medications will not count toward annual out-of-pocket spending caps.

Healthcare costs are one of the biggest concerns for many families and older adults. GLP-1 medication (glucagon-like peptide receptor agonist) costs can run up to $1,500 per month. Under the GLP-1 Bridge program, the price is a more affordable $50 monthly copay. This puts the treatment within reach of more people who could benefit from the drugs. Many retirees find medical costs more affordable in Mexico, but still cannot afford the costly GLP-1 drugs. This Bridge program is ideal for them.

The Health Benefits

Obesity has been a growing problem worldwide for decades. Currently, 72.4% of adults in the US over the age of 20 are overweight or obese, and 22.9% of teens are obese. On average, the current GLP-1 medication lowers body weight by 15%-20%, which can have a big impact on someone’s health. Obesity is associated with chronic health issues such as diabetes, hypertension, and heart disease.

The benefits of GLP-1 drugs go beyond just weight loss. Researchers have found that the drugs lead to better control of blood pressure and cholesterol. They can also improve arthritis and sleep apnea and reduce the risk of dementia.

Eligibility Requirements for Medicare Weight Loss Drug Coverage

Medicare beneficiaries currently on GLP-1 drugs through their Medicare Part D plan do not qualify for this Bridge program. Those using GLP-1 medications to manage their diabetes, sleep apnea, or fatty liver disease, and who don’t meet the weight requirements listed below are also excluded. Instead, they may qualify for GLP-1 coverage under their Medicare Part D plan. CMS is using BMI to determine the severity of obesity. Those eligible for the program must fall into one of the following categories:

1. Have a body mass (BMI) of 35 or more

2. Have a BMI between 30 and 34.99 AND have one or more of the following health problems:

   1. A history of heart attack or stroke

   2. Uncontrolled hypertension

   3. Prediabetes

   4. Diastolic heart failure

   5. Chronic kidney disease at stage 3a or worse

   6. Peripheral artery disease with symptoms

3. Have a BMI between 27 and 29.99 AND have one or more of the following health problems:

   1. A history of heart attack or stroke

   2. Prediabetes

   3. Peripheral artery disease with symptoms

Expectations for pilot program participants include working on lifestyle while taking the medication. This may include changes to their diet or exercise habits.

Next Steps for Getting Started

Medicare beneficiaries interested in learning more should talk with their healthcare provider. The provider can review your health history and potential eligibility. They can also discuss the risks and benefits of the medications with you. This is important because not everyone can tolerate or take the medications.

Medicare’s GLP-1 Bridge program could help improve the health of millions of Americans. One can only hope this pilot project will show enough success to continue after the current end date.